|
Basic Characteristics of Mutations
|
|
Mutation Site
|
R369S |
|
Mutation Site Sentence
|
Codon 325 mutations (C325Y/F/W/R) were the most common (108 specimens), followed by those at codon 369 (R369S/G/T/K, 13 specimens) and V236M (11 specimens). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL56 |
|
Standardized Encoding Gene
|
UL56
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
AD169
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cytomegalovirus infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
36170912
|
|
Title
|
Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing
|
|
Author
|
Chou S,Kleiboeker S
|
|
Journal
|
Antiviral research
|
|
Journal Info
|
2022 Nov;207:105422
|
|
Abstract
|
Genotypic testing for letermovir (LMV) resistance was performed by Sanger sequencing of cytomegalovirus terminase gene UL56 (codons 202-412) in 1165 diagnostic specimens, disclosing 36 sequence variants among 173 (14.8%) of the specimens, including one or more LMV resistance mutations in 134 specimens. Codon 325 mutations (C325Y/F/W/R) were the most common (108 specimens), followed by those at codon 369 (R369 S/G/T/K, 13 specimens) and V236M (11 specimens). Mutations V231L, N232Y, Q234R, L257F and V363I were detected in 1-3 specimens each. Combinations of codon 325 mutation and those at codons 236 or 369 were found in 6 specimens. Eleven novel sequence variants were phenotyped, validating Q234R, V363I and R369K as conferring 2- to 5-fold increased LMV 50% inhibitory concentrations (EC50). These findings indicate that UL56 codon 325 mutations conferring >3000-fold LMV EC50 are detected much more frequently in clinical practice than those conferring lower grade resistance, and suggest that a single step mutation to absolute LMV resistance is an ongoing concern in its therapeutic use.
|
|
Sequence Data
|
-
|